Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
I-131 MOv18
- Development stage
- Unknown
- Lead developer
- Fondazione IRCCS - Istituto Nazionale dei Tumori Di Milano
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraperitoneal
01
Overview
I-131 MOv18 is a radioimmunotherapeutic agent consisting of the murine monoclonal antibody MOv18 labeled with the radioactive isotope Iodine-131. The MOv18 antibody specifically targets the alpha-folate receptor (FR-alpha), a cell-surface glycoprotein that is highly overexpressed in the majority of non-mucinous epithelial ovarian cancers but has limited expression in normal tissues. When administered, typically via the intraperitoneal route to treat minimal residual disease, the antibody binds to FR-alpha on tumor cells, allowing the Iodine-131 to deliver localized beta radiation. This radiation induces DNA damage and cell death in the targeted malignant cells. Clinical studies have primarily focused on its use as a consolidation therapy for ovarian cancer patients with small-volume residual disease following chemotherapy.
- Other names
- Iodine-131 MOv18Iodine131 MOv18Iodine 131 MOv18MOv18-I131MOv-18-I131MOv 18-I131
02
Targets
FOLR1 (FRα)
Beyond the preview
Go deeper on I-131 MOv18.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on I-131 MOv18.